Introduction

33
As a dynamic system, cancer cells continuously adapt to the fluctuating microenvironment by 34 rerouting metabolic fluxes and evolve from early initiation through progression and 35 dissemination 1, 2 . Metabolic reprogramming in cancer cells facilitates energy production and 36 macromolecular synthesis to fuel cell proliferation 3, 4 . In addition to supporting bioenergetic and 37 biosynthetic needs, altered metabolism involves promiscuous production of non-canonical 38 metabolic intermediates, which have been described as metabolic waste products or metabolite 39 damage 5, 6 . Recent studies suggest that these previously uncharacterized metabolites including 40 oncometabolites are linked to 'non-metabolic' signaling mechanisms in cell-type-specific fate 41 decisions 7 . 42 The oncometabolite 2-hydroxyglutarate (2HG) occurs as two enantiomers and 43 accumulates up to millimolar concentrations in a broad range of hematological and solid 44 malignancies 8, 9 . Somatic mutations in isocitrate dehydrogenase genes, IDH1 and IDH2, found in 45 glioma and acute myeloid leukemia (AML) result in stereospecific production of the D-enantiomer 46 (D2HG) 10, 11 , while breast tumors frequently exhibit elevated levels of 2HG despite the lack of IDH 47 mutations 12, 13 8 cell subpopulation that is potentially less sensitive to oncometabolite perturbation. This was 159 contrasted with no pronounced differences in scATAC-seq accessibility profiles either across CpG 160 islands or H3K4me3 sites detected between the three experimental groups (Supplementary Fig. 161 2g). Together, single-cell DNA accessibility profiling revealed that the two enantiomers could 162 distinctly modulate the mammary epigenome and drive cell-to-cell epigenetic diversity in the 163 chromatin regulatory landscape.
164
2HG depletes promoter accessibility at highly methylated genes in breast cancer 165 To identify disease-relevant epigenetic signatures imposed upon 2HG exposure, we further 166 interrogated our scATAC-seq data using publicly available large-scale datasets including have two opposing impacts on the mammary epigenome, i.e., selective loss of accessibility in 179 active or poised chromatin and gain of accessibility in repressive or quiescent chromatin states.
180
The overall alterations in the chromatin landscape dynamics were particularly prominent in 181 response to L2HG, suggesting L2HG to be more potent in modulating the mammary epigenome. This is in line with earlier biochemical studies indicating that L2HG can competitively antagonize 183 αKG-dependent dioxygenases to a greater extent [18] [19] [20] . 184 To address the sparse nature of scATAC-seq data 37, 38 , we investigated regulatory 185 variation in single-cell measurements by aggregating scATAC-seq signals over transcription start 186 sites (TSS) in the genome. As shown in Fig. 3c with each color representing DNA accessibility 187 around TSS regions (n = 20,242) in a single cell, the chromatin occupancy pattern in untreated 188 control cells was highly concordant whereas the peaks were found to be diffused and 189 heterogeneous in exposed cells, suggesting enhanced epigenetic variability in regulatory 190 modules imposed by 2HG. However, the differences between exposed and unexposed cells were 191 not quantitatively remarkable when chromatin accessibility was assessed over all TSS regions 192 across the entire genome. In contrast, a marked reduction in accessibility was detected when a 193 set of highly methylated genes (n = 150) in breast tumors 44 was investigated (Fig. 3d and 194 Supplementary Fig. 3b ). Similar results were obtained using genes that were independently found 195 to be hypermethylated in promoter regions 28 (n = 150), indicating that 2HG led to reduced 196 chromatin accessibilities in gene promoters displaying DNA hypermethylation in breast cancer. In 197 contrast, no significant accessibility changes were observed in sets of genes that were highly 198 methylated in HMECs (data not shown) or other tumor types including endometrial cancer. Next, 199 we investigated epigenetic variability among the three L2HG subpopulations and found that L2 Fig. 6a,b) . The panel of metal-conjugated antibodies was designed 281 to detect both chromatin modifications and intracellular proteins including BRCA1, MSH2 and MLH1 that are involved in DDR and checkpoint signaling ( Supplementary Fig. 6a ). Consistent 283 with mass spectrometry measurements ( Fig. 1i and Supplementary Fig. 1e ), mass cytometry 284 analysis showed that 2HG exposure led to a substantial increase in all histone markers 285 investigated ( Supplementary Fig. 6c ). The biaxial gating of live single cells indicated a concurrent 286 increase in multiple distinct classes of histone methylation and the presence of cell populations 287 that were potentially less responsive to 2HG oncometabolites ( Supplementary Fig. 6c,d ). MLH1, which was restored upon withdrawal (Fig. 6f ). In addition, BRCA1 downregulation was 302 inversely correlated with H4K20 methylation (Supplementary Fig. 6e ) and, to our surprise, we 303 observed a remarkable association between the expression of the BRCA1 and MSH2 genes in 304 Cluster 1 (Fig. 6g) . Interestingly, this positive association was also evident in the CCLE cancer 305 cell lines as well as in the TCGA breast cancer cohort (Fig. 6h,i) . FlowSOM, flow cytometry data analysis using self-organizing maps. o t e r S t r o n g e n h a n c e r W e a k e n h a n c e r 0.0 I n s u l a t o r T x n t r a n s i t i o n T x n e l o n g a t i o n R e p r e s s e d Basal-like (n=97)
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